RCT of 406 patients with newly diagnosed stage IIIa/IIIb AL amyloidosis: anselamimab with cyclophosphamide, bortezomib and dexamethasone did not meet the primary end point vs placebo (win ratio 1.11; P=.332); a kappa subgroup (n=72) suggested lower mortality.
RCTn = 406
Wechalekar et al. Efficacy and Safety of Anselamimab in Immunoglobulin Light Chain Amyloidosis: Results From the Randomized CARES Trials